Trial Profile
A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs GS 030 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Acronyms PIONEER
- Sponsors GenSight Biologics
- 13 Feb 2023 Results published in the Gensight Biologics media release.
- 13 Feb 2023 According to Gensight Biologics media release, extension cohort patients are currently being recruited.
- 13 Feb 2023 According to Gensight Biologics media release, based on the good safety profile of GS-030, the Data Safety Monitoring Board (DSMB) recommended selecting the highest dose (5e11vg) for the extension cohort.